Shots:

• PerkinElmer to acquire IDS in all cash transactions for ~$155M. The transaction is expected to be completed in Q3’21
• The acquisition will allow PerkinElmer to foster its overall Diagnostics business and specifically its immunodiagnostics segment
• The acquisition will integrate PerkinElmer’s channel expertise and testing capabilities with IDS’ chemiluminescence products in endocrinology- autoimmunity- and infectious diseases to better serve customers across the globe

  Ref: Businesswire | Image: Wikipedia